Publication | Closed Access
Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
37
Citations
0
References
2022
Year
Hematological MalignancyAscent TrialMedicineMetronomic TherapyHematologyClinical TrialsDuration TherapyPharmacotherapyImmunotherapyOncologyRadiation OncologyHealth Sciences
No additional data available for this publication yet. Check back later!